Probing the Binding of Indolactam-V to Protein Kinase C through Site-Directed Mutagenesis and Computational Docking Simulations

Journal of Medicinal Chemistry
1999.0

Abstract

Protein kinase C (PKC) comprises a family of ubiquitous enzymes transducing signals by the lipophilic second messenger sn-1, 2-diacylglycerol (DAG). Teleocidin and its structurally simpler congener indolactam-V (ILV) bind to PKC with high affinity. In this paper, we report our computational docking studies on ILV binding to PKC using an automatic docking computer program, MCDOCK. In addition, we used site-directed mutagenesis to assess the quantitative contribution of crucial residues around the binding site of PKC to the binding affinity of ILV to PKC. On the basis of the docking studies, ILV binds to PKC in its cis-twist conformation and forms a number of optimal hydrogen bond interactions. In addition, the hydrophobic groups in ILV form "specific" hydrophobic interactions with side chains of a number of conserved hydrophobic residues in PKC. The predicted binding mode for ILV is entirely consistent with known structure-activity relationships and with our mutational analysis. Our mutational analysis establishes the quantitative contributions of a number of conserved residues to the binding of PKC to ILV. Taken together, our computational docking simulations and analysis by site-directed mutagenesis provide a clear understanding of the interaction between ILV and PKC and the structural basis for design of novel, high-affinity, and isozyme-selective PKC ligands.

Knowledge Graph

Similar Paper

Probing the Binding of Indolactam-V to Protein Kinase C through Site-Directed Mutagenesis and Computational Docking Simulations
Journal of Medicinal Chemistry 1999.0
Structural Basis of Binding of High-Affinity Ligands to Protein Kinase C:  Prediction of the Binding Modes through a New Molecular Dynamics Method and Evaluation by Site-Directed Mutagenesis
Journal of Medicinal Chemistry 2001.0
Modeling, Chemistry, and Biology of the Benzolactam Analogues of Indolactam V (ILV). 2. Identification of the Binding Site of the Benzolactams in the CRD2 Activator-Binding Domain of PKCδ and Discovery of an ILV Analogue of Improved Isozyme Selectivity
Journal of Medicinal Chemistry 1997.0
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V
Bioorganic & Medicinal Chemistry Letters 2000.0
Synthesis of the benzofuran analogue of ILV, a new protein kinase C (PKC) activator
Bioorganic & Medicinal Chemistry Letters 1994.0
Clarification of the Binding Mode of Teleocidin and Benzolactams to the Cys2 Domain of Protein Kinase Cδ by Synthesis of Hydrophobically Modified, Teleocidin-Mimicking Benzolactams and Computational Docking Simulation
Journal of Medicinal Chemistry 1998.0
Synthesis and protein kinase C binding activity of benzolactam-V7
Bioorganic & Medicinal Chemistry Letters 1999.0
Synthesis of structural analogs of lyngbyatoxin A and their evaluation as activators of protein kinase C
Journal of Medicinal Chemistry 1991.0
The amide hydrogen of (−)-indolactam-V and benzolactam-V8’s plays a critical role in protein kinase c binding and tumor-promoting activities
Bioorganic & Medicinal Chemistry Letters 2001.0
Novel conformationally constrained analogues of diacylglycerol. Protein kinase C binding affinity of simplified compounds based on a 6-membered lactam moiety
Bioorganic & Medicinal Chemistry Letters 1997.0